Abbott Laboratories (ETR:ABL)

Market Cap	159.97B -14.6%
Revenue (ttm)	37.75B +5.7%
Net Income	5.56B -51.3%
EPS	3.17 -51.3%
Shares Out	n/a
PE Ratio	28.79
Forward PE	19.14
Dividend	2.07 (2.30%)
Ex-Dividend Date	Jan 15, 2026

Volume	1,067
Average Volume	1,289
Open	92.22
Previous Close	90.32
Day's Range	92.22 - 92.64
52-Week Range	88.57 - 134.14
Beta	0.72
RSI	22.94
Earnings Date	Jan 22, 2026

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1888
• Employees: 115,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ABL

Financial Performance

In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.52 billion, a decrease of -51.13%.

Financial numbers in USD